Illumina deal for Grail could hurt innovation, EU warns
Reuters
Published Jul 22, 2021 12:19PM ET
Updated Jul 22, 2021 02:42PM ET
By Foo Yun Chee
BRUSSELS (Reuters) -U.S. life sciences company Illumina Inc (NASDAQ:ILMN)'s proposed acquisition of cancer test maker Grail Inc could curb innovation and competition, EU antitrust regulators warned Thursday as they opened a full-scale investigation.
The European Commission's announcement confirmed a Reuters story last week.
Illumina announced the $8 billion cash-and-stock deal for startup Grail last September, buying out investors including Amazon (NASDAQ:AMZN) founder Jeff Bezos, to regain control of a company it spun out five years ago.
Grail makes a non-invasive, early detection biopsy test to screen for many kinds of cancers using DNA sequencing.
The EU executive, which acts as the competition enforcer for the 27-country bloc, said its preliminary investigation showed that Illumina could have an economic incentive to block Grail's cancer detection rivals.
"It is very important to preserve market conditions, allowing the best solutions to emerge for the tests to ultimately reach the market at affordable prices," Commission Executive Vice-President Margrethe Vestager said in a statement.
The EU watchdog will decide by Nov. 29 whether to clear or block the deal.
Illumina said it will work with the Commission but warned against a veto of the deal.
"Re-uniting GRAIL with Illumina will accelerate availability of the GRAIL test by many years in the EEA and globally, saving tens of thousands of lives, and leading to significant health care cost savings," said CEO Francis deSouza in a statement.
In Washington, the U.S. Federal Trade Commission has filed a complaint seeking to block the deal, arguing that Illumina is the sole provider of the DNA sequencing that Grail uses and could prevent others from entering the market.
To address antitrust concerns, deSouza told Reuters on Thursday that Illumina had offered a 12-year contract to supply its technology to potential rivals.
He also argued that Illumina was best placed to broadly market the test. "This is all about access," he said of the proposed deal. "This will be a test for the rich otherwise, for a while."
The deal will face an August trial at the FTC.
While seeking EU approval for the deal, Illumina is also challenging in court the EU decision to examine it even though it does not meet the revenue criteria. Regulators say such powers are necessary to prevent companies buying rival start-ups to close them down.
Get The News You Want
Critics however say it creates uncertainties for companies.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.